Kimberly Burlison leads the North America Market Access function at Orchard Therapeutics, where she is responsible for U.S. access strategy for Lenmeldy, a first-in-class gene therapy for metachromatic leukodystrophy, a rare and life-threatening pediatric disease. She brings deep expertise in payer ...

Preet M. Chaudhary, MD, PhD, is Professor of Medicine at the University of Southern California (USC) in Los Angeles, where he serves as Chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases and holds the Ronald Bloom Family Chair in Lymphoma Research. He is...

George Church is Professor of Genetics at Harvard Medical School and Director of  PersonalGenomes.org, which provides the world's only open-access information on human Genomic, Environmental & Trait data (GET Conference). His 1984 Harvard PhD included the first methods for direct genome...

Dr. Daniel Cohen leads the Vector Engineering, Genomics, and Computational Biology team at the Roche Innovation Center - Philadelphia. His team leads technology innovation efforts in payload designs for AAVs, application of next generation sequencing and bioinformatics approaches to developing...

Robert O. (Bob) Dillman, M.D., is a Clinical Professor of Medicine at the University of California, Irvine, and since 2016 has been the Chief Medical Officer for AIVITA Biomedical Inc., Irvine, CA. Dr. Dillman received a B.A. from Stanford, M.D., internal medicine training, and Chief Resident...

Mr. Huang joined Ultragenyx in May 2015 and is responsible for leading global technical and pharmaceutical development, manufacturing and supply chain functions covering broad technical modalities including small molecules, recombinant proteins, nucleic acid medicines, and AAV gene therapy. This...

Lavakumar (Kumar) Karyampudi is Senior Director, Cell Therapies at Moffitt Cancer Center. He joined Moffitt Cancer Center in September of 2021. At the Moffitt Cell Therapies Facility, Kumar is responsible for the complete oversight of all technical staff activities, manufacturing, and compliance...

Dr. Elena Maryamchik earned a dual MD/MBA degree from the University of Miami in 2016. She subsequently completed a residency in Clinical Pathology at Massachusetts General Hospital, followed by fellowships in Cell and Gene Therapy at the University of Pennsylvania/Children’s Hospital of...

Chris Mason MD, PhD, FRSB, FRCS, FMedSci Chris is a leading international expert in cell and gene therapy with over 30 years of experience spanning R&D (including AI/ML), clinical medicine, regulation, manufacturing, reimbursement, and commercialization. He is Full Professor of Cell and Gene...

Dedicated to transforming scientific discoveries into life-changing therapies, Dr. Samarendra Mohanty co-founded Nanoscope Therapeutics and serves as President and Chief Scientific Officer. With over 20 years of experience in biomedical sciences, Dr. Mohanty has co-founded several biotech and...

Art Sagoskin MD is a Reproductive Endocrinologist and is an innovator, team-player, scientist, change-maker, and pioneer. For over four decades.Currently, he is involved with the Mygogenesis LLC and Amebogenesis companies and he has been part of the team promoting and researching the use of stem...

Abraham Scaria brings 25+ years of experience in gene therapy, ranging from discovery research to early-stage clinical trials. Abraham is currently the Chief Scientific Officer at Beacon Therapeutics. Most recently, he was CSO at AGTC leading the ophthalmology & neuroscience research...

Dr. Sahar Tavakoli is an Associate Teaching Professor and Director of the Cell and Gene Therapy Programs in the Department of Biology at Northeastern University. She earned her Ph.D. in Stem Cell and Developmental Biology from the National University of Singapore and completed postdoctoral training ...

Leveraging his expertise in immunology, Chandrav uses the Organ on Chip platform to investigate the role of the human immune system in multiple disease areas. His research primarily focuses on the development and utilization of Immune Organ Chip models for a better understanding of human-specific...

Immediate Past President and Board of Directors member of the International Society of Cell and Gene Therapy (ISCT) from June 2026. Previously President ISCT 2024 to 2026. Chief Commercialization Officer and Chair of the ISCT Commercialization Committee (2014-2020). CEO and Co-Founder of Kiji...

Dr. Hanley is the Chief and Director of the Cellular Therapy Program and an associate professor of pediatrics at Children’s National Hospital and George Washington University, respectively. He oversees processing for standard of care stem cell transplantation as well as the...

Christopher Juenger is Director of Regulatory Science, Policy, and Intelligence – North America Lead for CSL. In this role, he shapes regulatory policy through strategic engagement with external and internal stakeholders aligned with CSL’s portfolio of biotherapeutics for rare and serious...

Manolis Kellis is a Professor of Computer Science at MIT, a member of the Broad Institute of MIT and Harvard, and a member of the Computer Science and Artificial Intelligence Lab at MIT where he directs the MIT Computational Biology Group (compbio.mit.edu). His research is in disease...

Strategic Regulatory CMC Leader with extensive expertise in Cell & Gene Therapies (CGT), biologics, and tissue engineering. Proven track record of navigating the transition from early-phase development to commercial lifecycle management. Expert at authoring robust BLA/MAA/IND submissions and...

Fred Chereau is Chief Executive Officer of Sensorion since June 2026. He brings nearly 30 years of international leadership experience spanning biotechnology, pharmaceuticals, and medical devices, with a proven track record of building innovative companies, driving strategic growth, and advancing...

Amy House is Vice President of Corporate Development and Communications at Beacon Therapeutics, a clinical-stage biotechnology company advancing gene therapies for ocular diseases. She brings over 20 years of experience across healthcare and the life sciences spanning industry, academia, and...

Brock Reeve is the CEO and Co-Founder of Eos BioInnovation, an early-stage investment company focused on the regenerative medicine field. Eos is dedicated to incubating and seeding companies across modalities and indications based on research from leading academic labs. Prior to forming Eos in...